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Summary
We set out to clone Bax-specific CD8+ T cells from peripheral blood sam-
ples of patients with primary chronic lymphocytic leukaemia. A number
of clones were generated using a Bax peptide pool and their T-cell epitope
was mapped to two peptides sharing a common 9-amino-acid sequence
(LLSYFGTPT), restricted by HLA-A*0201. However, when these T-cell
clones were tested against highly purified syntheses (> 95%) of the same
peptide sequence, there was no functional response. Subsequent mass
spectrometric analysis and HPLC fractionation suggested that the active
component in the original crude peptide preparations (77% pure) was a
peptide with a tert-butyl (tBu) modification of the tyrosine residue. This
was confirmed by modification of the inactive wild-type sequence to gen-
erate functionally active peptides. Computer modelling of peptide:HLA-
A*0201 structures predicted that the tBu modification would not affect
interactions between peptide residues and the HLA binding site. However,
these models did predict that the tBu modification of tyrosine would
result in an extension of the side chain out of the peptide-binding groove
up towards the T-cell receptor. This modified product formed < 1% of
the original P603 crude peptide preparation and < 005% of the origi-
nal 23-peptide mixture used for T-cell stimulation. The data presented
here, illustrate the potential for chemical modifications to change the
immunogenicity of synthetic peptides, and highlight the exquisite capacity
of T-cell receptors to discriminate between structurally similar peptide
sequences. Furthermore, this study highlights potential pitfalls associated
with the use of synthetic peptides for the monitoring and modulating of
human immune responses.
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Introduction
Synthetic peptides containing immunogenic T-cell epi-
topes have been widely used in various aspects of immu-
notherapy from adoptive cell transfer1 to peptide
vaccination.2 This approach provides a cost effective and
reliable source of antigens that can be synthesized to suit-
able quantities and purity grades. This process eliminates
the introduction of potential virulence factors, which may
occur with the use of recombinant viral vaccines. Further-
more, the nature of the chemical synthesis process allows
for peptides to be modified to exacting specifications that
can enhance their MHC binding capacity, their in vivo
stability3 and ultimately their immunogenicity.2,4
Historically mixtures of synthetic peptides containing
multiple epitopes originating from specific proteins have
been used to measure human memory T-cell responses
against viruses such as human cytomegalovirus,5 Epstein–
Barr virus6 and human papillomavirus.7 Through the use
of smaller and more refined peptide mixtures it is possi-
ble to map the precise epitope specificity of individual T-
cell clones.8 Such epitopes can then be incorporated into
tetramer reagents to allow direct ex vivo measurement of
memory T cells in response to natural infection or vacci-
nation.9
In a previous study, we used pooled synthetic peptide
mixtures as immunogens to generate human T cells
(from healthy donors) against candidate tumour antigens
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in vitro. This approach allowed us to test the concept that
Bax, a pro-apoptotic protein that is abnormally degraded
in human cancers, can generate T cells with activity
against primary human cancer cells.8
In the current study, we used the same approach, but
using blood from patients with chronic lymphocytic leu-
kaemia (CLL) in an attempt to generate Bax-specific T-
cell clones. We used a combined immunological (for the
assessment of T-cell function and response) and physico-
chemical (for the identification and characterization of
peptides) approach to map a human CD8+ T-cell clone
specificity to a novel synthetic epitope. This finding high-
lights the immunogenicity of chemically modified pep-
tides and has implications for the use of synthetic
peptides to generate tumour-specific T cells.
Materials and methods
Blood samples
Healthy volunteer blood samples were collected locally
and CLL samples were derived from clinics at the Univer-
sity Hospital of Wales and Llandough Hospital. All sam-
ples were collected with informed consent with ethical
approval [South East Wales Research Ethics Committee
(02/4806)]. Peripheral blood mononuclear cells were iso-
lated by Histopaque-1077 (Sigma-Aldrich, Poole, UK)
centrifugation, as previously described.10
Induction of Bax-specific T cells
CD8+ T cells were immunomagnetically enriched from
peripheral blood mononuclear cells using anti-human
CD8 microbeads according to the manufacturer’s instruc-
tions (Miltenyi Biotec, Woking, UK). After enrichment,
the T cells were cultured at 37°/5% CO2 for 48 hr in AB-
RPMI medium supplemented with interleukin-7 (IL-7;
10 ng/ml; Peprotech, London, UK) to allow for the activa-
tion of autologous CLL cells to be used as a source of anti-
gen-presenting cells. AB-RPMI consisted of RPMI-1640
(Sigma-Aldrich) supplemented with 5% human AB serum,
glutamine (2 mmol/l), streptomycin (100 lg/ml), penicil-
lin (100 U/ml), HEPES (25 mmol/l) (all sourced from Life
Technologies, Paisley, UK). After 48 hr the T cells were
harvested, washed and cultured in the presence of irradi-
ated activated autologous CLL cells at a 4 : 1 ratio in AB-
RPMI supplemented with Bax peptide pool (10 lg/ml; Mi-
motopes, Clayton, Victoria, Australia)8 and IL-2 (40 U/ml;
Proleukin, Novartis, Frimley, UK). After 3 days, 500 ll of
AB-RPMI supplemented with IL-2 (120 U/ml) and IL-7
(30 ng/ml) was added. The cultures were re-stimulated
weekly with the peptide pool and autologous activated
CLL cells. On day 35 the T cells were harvested and Bax
peptide immunogenicity was tested by ELISpot assay.
Isolation and cloning of peptide-specific T cells
Peptide specific interferon-c (IFN-c) production was
induced after culturing the polyclonal T cells with the
Bax peptide pool (10 lg/ml) presented on autologous
activated CLL cells for 5 hr at 37°/5% CO2. Interferon-c
secreting T cells were immunomagnetically enriched using
anti-human IFN-c beads according to the manufacturer’s
protocol (Miltenyi Biotec). The isolated T cells were
‘rested’ overnight in AB-RPMI supplemented in IL-2
(40 U/ml) and IL-7 (10 ng/ml) before cloning by limiting
dilution as previously described.8
Measurement of IFN-c release
For IFN-c ELISA, T cells (1 9 105) were cultured in
200 µl of AB-RPMI at a 1 : 1 ratio with peptide-pulsed
T2 cells for 18 hr in U-bottomed tissue culture plates. T
cells were also cultured with unpulsed T2 cells (negative
control) or mitogen (positive control – phytohaemagglu-
tinin, 10 µg/ml, P1585 – Sigma Aldrich). Cell-free super-
natants were harvested and analysed by ELISA for human
IFN-c (Human IFN-c ELISAPRO kit; Mabtech, Nacka
Strand, Sweden).
Interferon-c ELISpots were performed as previously
described.7 Briefly, T cells were plated in triplicate at
1 9 105 (initial screen) or 1 9 104 to 3 9 104 cells
(clones/lines) per well in MultiScreen HTS IP Filter Plates
(Millipore, Watford, UK). T cells were cultured at 1 : 1
ratio with T2 cells  Bax peptides (10 lg/ml). T cells
were also incubated in the absence of T2 cells (negative
control) or with mitogen (positive control). The plates
were developed using the AP Conjugate substrate kit
(BioRad, Hemel Hempstead, UK). The numbers of spots/
well were counted with an ELISpot reader (AID, Oxford
Biosystems Cadama, Wheatley, Oxfordshire, UK). Specific
peptide responses were calculated by subtracting the back-
ground response (T cells + T2) from the T
cells + T2 + peptide wells.
For IFN-c ELISA intracellular cytokine staining, T
cells (1 9 105) were cultured in AB-RPMI at 1 : 1 ratio
with T2 cells  peptide in the presence of GolgiStopTM
and GolgiPlugTM (BD, Oxford, UK). T cells were also
cultured in the presence of mitogen (positive control).
After 5 hr the cells were washed and co-stained with
anti-human CD3-FITC (Biolegend, London, UK – clone
UCHT1) and CD8-peridinin chlorophyll protein (Bioleg-
end – clone HIT8a). The cells were then fixed and per-
meabilized with LeucopermTM (AbD Serotec, Kidlington,
UK) and intracellular IFN-c was identified using anti-
human IFN-c-phycoerythrin (eBioscience, Hatfield,
UK – clone 4S.B3). The cells were analysed using an Ac-
curi C6 (BD) and data analysis was performed using
CFLOW software (BD).
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CD107a surface staining
T cells (1 9 105) were cultured in AB-RPMI at 1 : 1 ratio
with T2 cells  peptide in the presence of GolgiStopTM
and GolgiPlugTM (BD). T cells were also cultured in the
presence of mitogen (positive control). Changes in the
surface expression of CD107a were determined through
the addition of anti-human CD107a-phycoerthrin (Bio-
legend – clone H4A3) to each culture. After 5 hr the cells
were washed and co-stained with anti-human CD3-FITC
(Biolegend – clone UCHT1) and CD8-peridinin chloro-
phyll protein (Biolegend – clone HIT8a). The cells were
analysed using an Accuri C6 (BD) and data analysis was
performed using CFLOW software (BD).
Peptides
Twenty-three candidate peptides were identified from the
amino acid sequence of Bax using predictive computer
algorithms for HLA binding, as previously described.8
Aliquots from these stock peptides were pooled (Bax pool
601–23) and stored at 80°. Smaller pools of five or six
peptides were made for epitope mapping. Highly purified
(> 95%) Bax P603 peptides were synthesized (ProIm-
mune, Oxford, UK and Peptide Synthetics, Bishops Wal-
tham, UK). Highly purified (> 98%) Bax P603 tBu
peptide was synthesized using t-butyl-modified tyrosine
(PolyPeptide Group, Strasbourg, France).
Peptide analysis
Liquid chromatography mass spectrometry (LCMS) was
performed on an Ultimate 3000 (Dionex, Sunnyvale, CA)
HPLC system interfaced to an amaZon SL ion trap spec-
trometer (Bruker, Billerica, MA). Chromatographic sepa-
ration was performed with a 100 9 21 mm Ace Excel 2
column at a flow rate of 05 ml/min, eluting with a bin-
ary gradient of acetonitrile/water (01% formic acid). The
column was equilibrated for 5 min with 5% acetonitrile,
followed by a linear gradient to 95% acetonitrile over
20 min. MS2 spectra were collected using collision-
induced dissociation with automatic or manual precursor
selection. Specific single amino acid deletion peptides
were identified using multiple reaction monitoring of
each of the corresponding [M + H]+ precursor ions.
Peptide library synthesis
Peptides were synthesized manually on Rink Amide meth-
ylbenzhydryl amine resin (Novabiochem, Watford, UK)
using standard fluorenylmethyloxycarbonyl (Fmoc) proto-
cols, as previously described.11 To prepare the libraries,
the resin was split into three 50 mg portions (1–3) and
single amino acid deletions were introduced into the C-
terminal residues (GTPT, portion 2) and the N-terminal
residues (LSYF, portion 3). After coupling of the
sequence LLSYFGTPT (portion 1), a 20 mg peptide-resin
sample was withdrawn and subjected to a further depro-
tection-coupling cycle with FmocLeu-OH to obtain
LLLSYFGTPT (portion 4).
Fractionation of peptide
Fractionation of LLSYFGTPT-NH2 (portion 1) was per-
formed by HPLC (Waters 2525 pump and 2996 detector;
Waters Corporation, Milford, MA) with a Vydac 218TP
250 9 22 mm column. Peptides were eluted with a bin-
ary gradient of 0 min 95% A/5% B, 1 min 95% A/5% B,
16 min 50% A/50% B where solvent A = H2O, 005% tri-
fluoroacetic acid (TFA) and solvent B = acetonitrile,
005% TFA at a flow rate of 229 ml/min. The principal
peak eluted at 115 min, with further peaks collected at
91, 94, 100, 104, 139, 144 and 153 min.
Modification of wild-type P603 peptide
An aliquot of P603 (Peptide Synthetics, 95% Pure) in
DMSO was added to diethyl ether and shaken vigorously
to precipitate the peptide. Subsequently the precipitated
peptide was recovered by centrifugation, washed with
diethyl ether and dried in vacuo. The peptide was treated
under different conditions to introduce tBu groups into
the wild-type (wt) peptide sequence.
Briefly, P603 peptide was added to a solution of di-tert-
butyl dicarbonate (12 mg) in CHCl3. The CHCl3 was evap-
orated by a stream of N2, then TFA (1 ml), triisopropylsi-
lane (25 µl) and water (25 µl) were added. After 1 hr, the
solution was concentrated by N2 blowing to approximately
50% of its original volume, then pipetted into diethyl ether
(14 ml). Precipitate was collected by centrifugation,
washed twice with diethyl ether and allowed to dry in air.
P603 was also dissolved in TFA (1 ml) and methylpro-
pene (Sigma-Aldrich) was bubbled through the solution
for 15 min. The solution was blown with a stream of N2
to evaporate volatile material and extracted with water
(14 ml). The aqueous extract was concentrated by rotary
evaporation then lyophilized.
MHC:peptide model preparation
The starting model was based on entry 4I4W12 from the
Protein Data Bank (http://www.rcsb.org). COOT13 was
used to modify the sequence of the peptide to be
LLSYFGTPT. The conformation of the peptide was
restricted to be as close as possible to that in 4I4W. For
the purpose of the present work, this model was referred
to as ‘wild type’, or wt. Y4 of the peptide was modified
by adding a tBu group at the meta position of the aro-
matic ring of the tyrosine side-chain. As this ring can
rotate between two positions around the v2 dihedral, two
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possible conformations need to be considered (Fig. 6).
The geometry of the Tyr(3-tBu) was regularized by apply-
ing the geometry restraints generated with JLIGAND.14
PYMOL was used to generate the graphical representa-
tions in Fig. 7.
Results
Detection and isolation of Bax peptide-specific T cells
Our original aim was to isolate from patients with CLL
CD8+ T-cell clones specific for peptides derived from the
pro-apoptotic protein, Bax. Subsequently a Bax peptide
pool (P601–623) was used to stimulate CD8+ T cells isolated
from HLA-A*0201+ patients and Bax immunogenicity was
assessed by IFN-c ELISpot. After 5 weeks of peptide stimula-
tion a highly significant (P = 00008) Bax-specific response
was observed from patient R6A8R89 (Fig. 1a).
Bax-specific CD8+ T cells were immunomagnetically
enriched on the basis of IFN-c secretion and cloned by
limiting dilution. Six lines (6C2, 6E2, 6C5, 8C9, 7F7 and
9D7) exhibited positive Bax responses (> 20 spots/
3 9 104) and were selected for further characterization
(Fig. 1b). The putative T-cell clones were first tested
against the full peptide pool to reaffirm Bax specificity;
then against four smaller sub pools (Bax P601–606, Bax
P607–612, Bax P613–618 and Bax P619–623) to narrow
down the response, followed by individual peptides for
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Figure 1. T-cell responses against Bax peptides and mapping the specificity of the CD8+ T-cell clone 6C5. (a) Purified CD8+ T cells were cul-
tured with irradiated autologous activated B-CLL cells and Bax peptides 601–23 for 5 weeks before testing by interferon-c (IFN-c) ELISpot. Anti-
gen-presenting cells (APC) were autologous activation B-CLL cells. Numbers shown are spots/105 T cells (mean of triplicates  SD, n = 1)
Statistical analysis (unpaired two-tailed t-test) was carried out using GRAPHPAD PRISM (GraphPad Software, Inc., La Jolla, CA). (b) T-cell cultures
generated by limited dilution were tested for the recognition of Bax peptides 601–23 by IFN-c ELISpot. T cells were plated (~2 9 104 to
3 9 104/well) with APC or with APC + peptides at a 1 : 1 ratio. APC were T2 cells. Background responses (T cells + T2) were subtracted from
the data (n = 1). (c) 6C5 was tested by IFN-c ELISpot against the Bax peptide pool 601–23, split pools, and individual peptides. T cells were pla-
ted (1 9 104/well) in triplicate with T2 or T2 + peptides at a 1 : 1 ratio. Background response (T cells + T2) was subtracted from the data (5
SFC/104 cells) (mean  SD of triplicates, n = 2). (d) 6C5 was assayed against T2 cells pulsed with varying concentrations (20–625 lg/ml) of
Bax P603 and Bax P605 at 1 : 1 ratio for 18 hr. Cell-free supernatants were harvested and tested for the presence of IFN-c by ELISA. The EC50
value was calculated using the fitted curve, P603 – 492 µM and P605 > 100 µM (mean  SD of duplicates, n = 3).
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epitope identification (Fig. 1c). T-cell clones 6C5 and
8C9 both exhibited positive responses against the full
Bax peptide pool and the sub-pool Bax P601–606. Of the
peptides within the Bax P601–606 pool, only P603 and
P605 induced an ELISpot response (Fig. 1c). Interest-
ingly, these two peptides shared an overlapping nine
amino acid sequence: Bax P603 is a 9mer (Bax161–169;
LLSYFGTPT) and Bax P605 is a 10mer (Bax160–169;
GLLSYFGTPT). T-cell receptor (TCR) Vb chain staining
was performed and indicated the presence of a single Vb
chain (Vb 13.1) in both lines, indicating clonality (data
not shown). Of the two clones identified, 6C5 was
selected for further characterization because of its supe-
rior growth kinetics.
Peptide dose–response experiments confirmed that 6C5
recognized both peptides (P603 and P605) but had a
greater avidity for P603 as determined by comparison of
the EC50 values, P603 = 492 lM and P605 > 100 lM
(Fig. 1d).
6C5 recognized crude but not highly purified P603
peptide
The initial results suggested that the T-cell clone 6C5
recognized the nine amino acid sequence (LLSYFGTPT)
common to P603 and P605 (Fig. 1c,d). As neither peptide
preparation was 100% pure it was possible that the
activation of 6C5 was associated with other peptide
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Figure 2. 6C5 recognition of crude P603 but not highly purified P603. Representative sample of flow cytometry analysis (three independent
experiments) of intracellular staining of interferon-c (IFN-c). T cells (1 9 105/tube) were cultured in the presence of T2 or T2 + Bax peptide
P603 (> 95% Pure, 10 lg/ml) or P603 (77% Pure, 10 lg/ml) at a 1 : 1 ratio for 5 hr. Lymphocytes were gated based on their forward and side
scatter profile and then doublet exclusion was performed based on forward scatter height versus forward scatter width. T cells were then gated
on CD3+ CD8+ cells and IFN-c production was assessed through intracellular staining with anti-IFN-c (mean  SD of duplicates, n = 3). Statis-
tical analysis (unpaired two-tailed t-test) was carried out using GRAPHPAD PRISM.
Table 1. Comparison of purified and crude P603 peptide samples by liquid chromatography mass spectrometry
Peptide r.t. (min) Transition Crude P603 Purified P603
LLSYGTPT 55 8515 ? 6173 (b6H2O) U U
LSYFGTPT 63 8854 ? 6513 (b6H2O) U U
LLSFGTPT 68 8355 ? 6013 (b6H2O) U U
LLSYFGTT 70 9015 ? 7644 (b7H2O) U U
LLSYFGTPT 71 9985 ? 7644 (b7H2O) U U
LLSYFTPT 71 9415 ? 7074 (b6H2O) ✗ U
LLSYFGTP 72 8975 ? 7644 (b7H2O) U ✗
LLYFGTPT 74 9115 ? 6774 (b6H2O) U U
LLLSYFGTPT 80 11116 ? 8775 (b8H2O) U ✗
LLSY(3-tBu)FGTPT 93 10546 ? 8205 (b7H2O) U ✗
Chromatography was performed on an Ace Excel 2 100 9 21 mm column (C18), eluting with a linear gradient of 5–95% acetonitrile (01% for-
mic acid) at 05 ml/min over 20 min. MS/MS spectra were measured on a Bruker amaZon SL ion trap spectrometer. The sequence and retention
times of each of the peptides identified are indicated. The presence (U) or absence (✗) of the peptides in each sample was assessed using
extracted ion chromatograms for the indicated transition.
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species (8mers, 10mers and modified 9mers). Therefore
6C5 was tested against highly purified P603 peptides
(> 95% pure) obtained from two independent commer-
cial sources (Proimmune and Peptide Synthetics). 6C5
failed to respond to the purified forms of P603 (95%
pure), however the original P603 preparation (77% pure)
induced a robust and highly significant (P < 00001)
IFN-c response (Fig. 2). These results suggested that the
immunogenicity associated with the original P603 (77%
pure) was not a result of the peptide sequence
(LLSYFGTPT).
Comparison of crude and highly purified P603
Samples of crude and purified P603 peptide were analy-
sed by ion trap LCMS (see Supporting information, Fig.
S1). The samples were investigated for the presence of
8mers, 10mers and modified 9mers (Table 1). Peaks cor-
responding to DF, DL, DY, DP, DT, DS 8mer peptides
were observed in both the crude and purified samples.
Fragmentation spectra of an ion of m/z 11116 and the
corresponding doubly charged ion were consistent with a
peptide carrying an additional N-terminal leucine residue,
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Figure 3. 6C5 recognizes a peptide present in fraction 8. (a) CD8+ T-cell clone 6C5 was cultured in the presences of various peptide preparations
representative of potential C-terminal (GTPT) and N-terminal (LSYF) deletions, as well as C-terminal additions. T cells (1 9 105/tube) were cul-
tured in the presence of T2 or T2 + peptides at a 1 : 1 ratio for 5 hr. Interferon-c (IFN-c) production was assessed through intracellular staining
with anti-IFN-c. To facilitate gating, the cultures were also co-stained with anti-CD3 and anti-CD8. Background (T-cells + T2) were subtracted
from the data (mean  SD, n = 3). (b) Fractionation was performed by HPLC (Waters 2525 pump and 2996 detector) with a Vydac 218TP
250 9 22 mm column. Peptides were eluted with a binary gradient of 0 min 95% A, 1 min 95% A, 16 min 50% A where solvent A = H2O,
005% trifluoroacetic acid (TFA) and solvent B = acetonitrile, 005% TFA at a flow rate of 229 ml/min. The chromatogram shows the absor-
bance at 220 nm. (c) CD8+ T-cell clone 6C5 was cultured in the presence of fractions (F1–F8) generated from the fractionation of the P1 peptide
preparation (crude full length 9mer, LLYSFGTPT). T cells (1 9 105/tube) were cultured in the presence of T2 or T2 + peptides at a 1 : 1 ratio
for 5 hr. Lymphocytes were gated based on their forward and side scatter profile and then doublet exclusion was performed based on forward
scatter height versus forward scatter width. T cells were then gated on CD3+ CD8+ cells and IFN-c production was assessed through intracellular
staining with anti-IFN-c. Background (T-cells + T2) was subtracted from the data (mean  SD, n = 3). Statistical analysis (unpaired two-tailed
t-test, in comparison to P603 > 95% Pure) was carried out using GRAPHPAD PRISM. Significance is indicated by ****< 00001, ***00001–0001,
**0001–001 and *001–005.
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LLLSYFGTPT. An ion of m/z 10546 was assigned as a
reaction product of the tyrosine side chain with tertiary
butyl cations liberated during the final deprotection and
cleavage of the peptide.
Identification of the immunogenic component of
crude P603
Based on the earlier observations, the activity of 8mer
and 10mer peptides was investigated by deliberate synthe-
sis of a small library of crude peptides. The library con-
sisted of four peptide preparations: (i) full length 9mer
(LLYSFGTPT); (ii) enhanced deletions of the C-terminal
residues (G/T/P/T); (iii) enhanced deletions of the N-ter-
minal residues (L/S/Y/F); (iv) 10mer (LLLSYFGTPT,
additional N-terminal leucine). All four peptide prepara-
tions induced similar levels of IFN-c secretion, suggesting
that neither a deletion peptide nor the 10mer in isolation
were responsible for 6C5 activation (Fig. 3a). These
results suggested a peptide entity common to all four
preparations and the original crude P603 synthesis.
The portion 1 preparation (crude full-length 9mer,
LLYSFGTPT) was fractionated by reverse phase HPLC,
with fraction collection guided by UV absorbance
(Fig. 3b). Individual fractions were collected, lyophilized
and assayed to determine their capacity to induce T-cell
activation. Activity was shown to be associated with a frac-
tion eluting at longer retention time than the principal
component (LLSYFGTPT) of the crude peptide prepara-
tion (Fig. 3c). LCMS analysis of the active fraction
revealed a peptide with m/z 10536 that exhibited an essen-
tially identical fragmentation pattern to the species pro-
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Tyr(3-tBu). Unmodified P603 (> 95% Pure) was reacted with methylpropene and trifluoroacetic acid (TFA), or Boc2O and TFA to induce tBu
groups on the tyrosine residue. (b) T cells (1 9 105/tube) were cultured in the presence of T2 or T2 + P603 (> 95% Pure, 10 lg/ml), P603
(77% Pure, 10 lg/ml) or the two P603 modified peptides (di-tert-butyl dicarbonate and methylpropene) at a 1 : 1 ratio for 5 hr. Lymphocytes
were gated based on their forward and side scatter profile and then doublet exclusion was performed based on forward scatter height versus for-
ward scatter width. T cells were then gated on CD3+ CD8+ cells and IFN-c production was assessed through intracellular staining with anti-IFN-
c. Background (T-cells + T2) were subtracted from the data (mean  SD, n = 3). Statistical analysis (unpaired two-tailed t-test, in comparison
to P603 > 95% Pure) was carried out using GRAPHPAD PRISM. Significance was indicated by ****< 00001.
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posed to contain Tyr(3-tBu), that was identified in the
crude P603 (see Supporting information, Fig. S1). The dif-
ference in m/z between the two species can be accounted
for by the differences in C-termini of the peptides, amide
versus acid, which arises due to the chemistry of the Rink
resin used for preparation of the peptide library.
Modification of P603
To investigate whether a peptide species containing Tyr
(3-tBu) was responsible for the observed T-cell activation,
the inactive wt P603 (95% pure) preparation was sub-
jected to conditions intended to generate tBu cations. It
was predicted that this treatment would re-introduce the
alkylated side products and confer activity to a previously
inactive wt sequence. Two peptide samples were treated
under different conditions, methylpropene with TFA and
di-tert-butyl dicarbonate with TFA, to mimic the final
step of peptide synthesis (Fig. 4a). Analysis of the reac-
tion products by HPLC and LCMS demonstrated the
introduction of peptides carrying the Tyr(3-tBu). This
was visible in both samples, and displayed the same
retention time and MS2 spectrum as the species observed
in the crude P603 (see Supporting information, Fig. S2).
Both of the Tyr(3-tBu) modified preparations were able
to induce IFN-c secretion; strongly suggesting that a Tyr
(3-tBu) modified peptide was responsible for the activity
(Fig. 4b).
P603 Tyr(3-tBu) stimulates the activation of 6C5
To confirm P603 Tyr(3-tBu) was responsible for the acti-
vation of 6C5, a highly purified (> 98%) peptide prepara-
tion was obtained from a commercial supplier
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Figure 5. Activation of 6C5 is induced by tBu P603. (a) and (b) Representative sample of flow cytometry analysis (three independent experi-
ments) of intracellular staining of interferon-c (IFN-c) and surface staining of CD107a, respectively. T cells (1 9 105/tube) were cultured in the
presence of T2 or T2 + P603 (> 95% Pure, 10 lg/ml), P603 (77% Pure, 10 lg/ml) or P603 tBu (> 98% Pure, 10 lg/ml) at a 1 : 1 ratio for 5 hr.
IFN-c production was assessed through intracellular staining with anti-IFN-c and CD107a expression through surface staining with anti-CD107a.
To facilitate gating, the cultures were also co-stained with anti-CD3 and anti-CD8 (mean  SD of duplicates, n = 3). Statistical analysis
(unpaired two-tailed t-test) was carried out using GRAPHPAD PRISM. (c) 5 9 105 T2 cells were pulsed with varying concentrations of P603 (77%
Pure, 10 lg/ml to 1 9 106 lg/ml) and P603 tBu (> 98% Pure, 10 lg/ml to 1 9 106 lg/ml). After 1 hr, unbound peptide was washed off and
the pulsed T2 cells were cultured with 1 9 105 6C5 CD8+ T cells at a 1 : 1 ratio. Cell-free supernatant was harvested and tested for the presence
of IFN-c by ELISA (mean  SD, n = 3). (d) 1 9 105 6C5 CD8+ T-cells were cultured at 1 : 1 ratio with T2 cells in the presence of varying con-
centrations of P603 (77% Pure, 10 lg/ml to 1 9 106 lg/ml) and P603 tBu (> 98% Pure, 10 lg/ml to 1 9 106 lg/ml) for 5 hr. Lymphocytes
were gated based on their forward and side scatter profile and then doublet exclusion was performed based on forward scatter height versus for-
ward scatter width. T cells were then gated on CD3+ CD8+ cells and changes in the surface expression of CD107a were determined through cul-
turing the cells in the presences of anti-CD107a (mean  SD, n = 3). The EC50 value was calculated using the fitted curve using GRAPHPAD
PRISM.
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(PolyPeptide Group). This peptide was able to stimulate
robust and highly significant (P < 00001) IFN-c and
CD107a responses in 6C5. However, the unmodified wt
P603 (95% pure) failed to induce T-cell activation in the
same assays (Fig. 5a,b).
Peptide dose–response experiments were performed to
validate the activity of P603 Tyr(3-tBu) and to compare
the activity of this peptide against the original crude (77%
pure) P603 preparation. P603 Tyr(3-tBu) (> 98% pure)
was more potent than P603 (77% pure) as determined by
comparison of the calculated EC50 values (Fig. 5c,d).
Using IFN-c production as a functional read-out, the EC50
values were 02 lM for P603 Tyr(3-tBu) (> 98% pure) and
14 lM for P603 (77% pure). By contrast using CD107a
expression as a read-out, the EC50 values were 052 nM for
P603 Tyr(3-tBu) (> 98% pure) and 610 nM for P603
(77% pure). For both assays the highly purified P603 Tyr
(3-tBu) was recognized with greater activity (1–3 logs)
than the crude P603 (77% pure). These results would be
predicted, as the Tyr(3-tBu) modified form of the peptide
was found by HPLC to comprise < 1% of the crude P603
(77% pure) preparation.
Collectively these findings confirm that the activation
of 6C5 is due to the modified P603 [LLSY(3-tBu)FGTPT]
rather than the wt P603 peptide (LLSYFGTPT). Molecular
modelling of these two peptides indicates that the
presence of the Tyr(3-tBu) results in an extension of the
tyrosine side chain out of the MHC towards the TCR
(Fig. 7a,b). Using the model we have predicted that the
presence of the Tyr(3-tBu) could result in a peptide with
the capacity to adopt two different conformations, due to
the rotation of the aryl ring (Fig. 6b–d). As the presence
of the Tyr(3-tBu) does not appear to affect the peptide
conformation or the position of the MHC anchor residue,
we predict that the discrimination between the modified
and unmodified peptides occurs largely at the level of the
TCR. Peptide binding was assessed by the up-regulation
of HLA-A*0201 expression on T2 cells. Neither the modi-
fied or unmodified peptide were able to significantly up-
regulate HLA-A*0201 in comparison to the positive con-
trol MART1 peptide, suggesting poor or weak binding
under the conditions used (see Supporting information,
Fig. S3). Nevertheless, the results suggest that the modi-
fied peptide does not have better binding to HLA-A*0201
than the unmodified peptide. This supports our hypothe-
sis that the primary effect of the Tyr(3-tBu) modification
is to alter interactions with the TCR.
χ2
(d)(a)
(b)
(c)
OH
CO2H
NH2
Figure 6. Peptide:MHC modelling of unmodified and Tyr(3-tBu)
modified peptides. Computer models illustrating the conformation
of peptides bound to HLA-A*0201 were generated based on entry
4I4W from the PDB. The HLA-A*0201 structure has been removed
for clarity. COOT was used to modify the sequence of the peptide to
be LLSYFGTPT. (a) The resulting modified peptide is capable of
adopting two possible conformations (b) and (c) due to the rotation
of the aromatic ring about its axis (d).
(a)
(b)
Figure 7. Peptide:MHC modelling of unmodified and Tyr(3-tBu)
modified peptide bound to HLA-A*0201. Computer models of Pep-
tide:HLA*0201 complexes were generated using entry 4I4W from the
PDB. COOT was used to modify the sequence of the peptide to be
LLSYFGTPT. (a) and (b) show that for both peptides the anchor
residues at either end of the peptide are well buried in the groove.
However, the presence of the tBu-modified tyrosine results in the
extension of the side chain out of the MHC and towards the T-cell
receptor, which is not observed with the wild-type peptide.
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Discussion
Minor modifications of antigenic peptides have been
shown to have profound positive and negative effects on
peptide recognition. These modifications can vary from
naturally occurring post-translation modifications15 to
specific synthetic alterations of the peptide sequence and/
or individual amino acids.4,16 These changes can alter
MHC binding; the three-dimensional tertiary peptide
structure and the TCR contact residues of the peptides,
and so alter peptide immunogenicity.
We describe the novel discovery of a human CD8+ T-
cell clone that recognizes a tBu-modified peptide LLSY(3-
tBu)FGTPT while showing no recognition of the wt pep-
tide LLSYFGTPT. This modification appears to have no
effect on the potential structure of the MHC:peptide
complex (Fig. 7a,b). But it does have a profound effect
on T-cell recognition. Similarly it has been observed that
a minor change in tyrosine, the conversion of tyrosine to
nitrotyrosine, can abrogate peptide recognition in both
CD4+ T cells17 and CD8+ T cells.18
Peptides containing Tyr(3-tBu) are synthetic entities
and do not occur in nature, so it is unclear how CD8+ T
cells with specificity for Tyr(3-tBu) peptides could arise.
There are two possibilities for the origin of T-cell clone
6C5. First, it could be a memory T-cell generated in vivo
against a naturally occurring epitope that is able to cross-
react on Tyr(3-tBu) peptides. Theoretically, a different,
naturally occurring residue that possesses an extended
side chain could have the correct dimensions to allow for
TCR contact. This could be tested by using large peptide
libraries to establish the amino acid preference of 6C5 for
each position in the peptide.19 Second, the clone could
have been generated from naive T cells primed against
P603 tBu in vitro. It is possible that such naive T cells
could have been activated and expanded to functionally
detectable levels during the 5-week culturing period.20
The identification of P603 Tyr(3-tBu) resulted from the
detection of a minor peptide contaminant (< 005%) pres-
ent within a crude pool of synthetic peptides. Historically,
synthetic peptide pools have been successfully used to gen-
erate peptide-specific T-cell responses and clones.8 How-
ever, one of the major drawbacks associated with this
process is the inability to produce completely pure peptide
preparations. Commercially produced peptides are com-
monly subject to stringent purification and quality check-
ing processes, such as reverse-phase HPLC and mass
spectrometry. Despite these efforts, contaminants can still
be present within the final peptide preparations, poten-
tially causing misleading results.21–24 This highlights the
potential risk that the presence of traces of highly immu-
nogenic contaminating peptides could result in misleading
assessment of clinical responses to peptide vaccines. Typi-
cally clinical grade peptides used during in vivo human
vaccine trials range in purity from 95 to ≥ 98%.25–31 As
the contaminant report here constituted < 1% of the ori-
ginal P603 crude peptide preparation and < 005% of the
original 23-peptide mixture it is conceivable that minute,
but highly immunogenic peptide species may be present
within clinical grade peptide vaccines. This could lead to
the induction of inappropriate responses in T cells with
the wrong specificity or even cause adverse reactions.
We believe that the tBu-modified peptide identified in
this report was generated during the peptide synthesis
process; most likely due to the alkylation of tyrosine by
tBu cations under peptide de-protection conditions. This
reaction has been reported during model de-protection
conditions32 and for preparative scale synthesis33 of Tyr
(3-tBu), therefore the observation of a peptide containing
Tyr(3-tBu) as a minor constituent of the crude P603
preparation is not surprising.
In conclusion, the data presented here highlight some
issues with interpreting data obtained when using synthetic
peptide mixtures. Additionally we have reported that the
chemical modification of a single amino acid, Tyr?Tyr
(3-tBu), can completely dictate activation of the CD8+ T-
cell clone 6C5. This peptide modification appears to exert
its primary effect via interaction with the TCR rather than
influencing the conformation of the peptide within the
HLA binding site. These findings emphasize the specificity
and sensitivity of TCR and their ability to discriminate
between peptides that have an identical primary amino
sequence but differ by a single chemical modification.
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online version of this article:
Figure S1. Liquid chromatography mass spectrometry
analysis of purified and crude P603 peptide samples.
Figure S2. MS2 spectra of Tyr(3-tBu) containing pep-
tides.
Figure S3. Peptide binding to HLA-A2.
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